ABSTRACT
Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection has been associated with a worldwide pandemic. We assessed data as of November 25, 2020 from our combined laboratories and as reported for states in the United States (US) and countries for case, death, and testing rates per million to determine causes of rate differences. SARS-CoV-2 naso-pharyngeal (NP) RNA testing in 1,179,912 subjects in 47 states (39 of which with >100 cases) are reported, with a mean 9.3% positive rate, comparable to the 7.0% rate reported nationwide. In 91 previously positive (2-4 weeks) subjects, NP swab testing was twice as likely to be positive (58.6%) as saliva samples (21.5%). We also documented that NP swabs could remain positive for 6 weeks or longer. Our positive rates per state agreed reasonably well with reported national data (r=0.609, P<0.0001). The highest US case rates per million were in the mid-west; the highest death and testing rates were in the northeast. Of 47 countries, the highest case, death, and testing rates per million were mainly in Europe and the Americas, with the lowest rates in Asia. Correlations between case and death rates and case and testing rates were very different between states (0.076 and -0.093, respectively) and countries (0.763 and 0.600, respectively). In conclusion, outpatient saliva testing was not as sensitive as NP testing for detection, and the marked variability in case and death rates was most likely due to differences in public health measures, viral and human genetic differences and age of cases, rather than due to differences in testing rates.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
not a clinical trial
Funding Statement
Support for this research was received from Boston Heart Diagnostics, Viracor-Eurofins Clinical Diagnostics and Scientific Network, Diatherix, and Trinity Health of New England. Many of the authors are either full-time or part-time employees of the reference laboratories supporting this study, that provide testing for healthcare providers. No payments were received from any third party to influence the results of the research.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All subject information was anonymized prior to data analysis, and all relevant ethical guidelines were followed. We have followed the STROBE Guidelines for Observation Studies. IRB oversight for patient data extracted from medical records without name or identification number and analyzed as anonymized data was provided by Advarra Institutional Review Board (Columbia, MD). As stated in the cover letter and in the manuscript, the determination of the Advisory Review dated 25. September 2020 was "had the request for exempt determination been submitted prior to initiation of research activities, the research would have met the criteria for exemption from IRB review under 45 CFR 46.104(d)(4)." The study population included a subset of 91 previously diagnosed COVID-19 subjects who were being evaluated as potential participants in an approved human IRB protocol at Trinity Health of New England (Hartford, CT).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The raw data from this study are available upon request to the corresponding author. Information on COVID-19 data for the United States was obtained from the Centers for Disease Control and Prevention (CDC) website on September 1, 2020, https://www.cdc.gov/covid-data-tracker/index.html#testing, as well as from https://www.worldometers.info/coronavirus/? and https://www.covid19.who.int/.
https://www.cdc.gov/covid-data-tracker/index.html#testing
Abbreviations
- CDC
- Centers for Disease Control and Prevention
- COVID-19
- coronavirus disease-2019
- EUA
- emergency use authorization
- FDA
- Food and Drug Administration
- N gene
- nucleocapsid gene
- NP
- naso-pharyngeal
- OP
- oro-pharyngeal
- PCR
- polymerase chain reaction
- RT-PCR
- reverse transcriptase polymerase chain reaction
- SARS-CoV-2
- severe acute respiratory syndrome coronavirus-2
- S gene
- spike glycoprotein gene
